Fig. 6.

A proposed mechanism where Dexibuprofen could constitute a potential treatment for AD. DXI causes a reduction in neuroinflammatory process which decreases three key signaling pathways, CABLES/c-ABL, hippocampal insulin pathway and the β-secretase enzyme, which are directly involved in the production and metabolism of Aβ, TAU phosphorylation and memory improvement. These signaling pathways constitute an early target for the treatment of AD with DXI, probably in a presymptomatic stage which can explain the potential use of this drug in neurodegenerative diseases.